European Commission Approves Bristol-Myers Squibb’s Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of Chronic Hepatitis C Infection DAKLINZA BMS' drug has also been given a broad label; it can be used in the four main strains of hepatitis C (genotypes 1, 2, 3, and 4) as well as in patients with advanced liver disease and who have failed prior treatment with HCV protease inhibitors such as Merck & Co's Victrelis (boceprevir) and Vertex' Incivek (telaprevir) ------------- Daklinza film-coated tablets _________ Daclatasvir وللمعلومية اكثر Daclatasvir Its Back: Daclatasvir Plus Sofosbuvir-Three HCV Clinical Trials Sponsored By Bristol-Myers Squibb #علاج فيروس سى جديد _واحنا نايمين_#BMS’s #Daklinza, potential cure for #hepatitis C, to curb rise of associated liver disease & #cancer New miracle cure for deadly Hepatitis C+#علاج فيروس سى _#Daklinza,#دكلينزا,daklinza_وداعا ل #بيزنس الكبد فى... by ا...